• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $IONS

    Ionis Pharmaceuticals Inc.

    Subscribe to $IONS
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

    IPO Year:

    Exchange: NASDAQ

    Website: ionispharma.com

    Peers

    $ALNY
    $BIIB

    Recent Analyst Ratings for Ionis Pharmaceuticals Inc.

    DatePrice TargetRatingAnalyst
    7/1/2025$57.00Equal Weight → Overweight
    Barclays
    4/7/2025$45.00Buy
    H.C. Wainwright
    3/31/2025$39.00Neutral
    Redburn Atlantic
    8/2/2024$67.00 → $60.00Outperform → Market Perform
    BMO Capital Markets
    7/24/2024$53.00 → $62.00Market Perform → Outperform
    Leerink Partners
    7/16/2024$29.00 → $75.00Buy
    Jefferies
    6/14/2024$44.00Underperform → Mkt Perform
    Bernstein
    4/10/2024$58.00Peer Perform → Outperform
    Wolfe Research
    1/2/2024$52.00 → $62.00Neutral → Buy
    BofA Securities
    10/23/2023$33.00 → $52.00Underperform → Neutral
    BofA Securities
    See more ratings

    Ionis Pharmaceuticals Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Yang Michael J.

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      7/2/25 4:53:41 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Parshall B Lynne

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      7/2/25 4:53:31 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Wender Joseph H

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      7/2/25 4:53:35 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Loscalzo Joseph

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      7/2/25 4:53:21 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Klein Joseph Iii

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      7/2/25 4:53:14 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Herman Joan E

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      7/2/25 4:53:09 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Hayden Michael R

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      7/2/25 4:53:02 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Diaz Allene M.

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      7/2/25 4:52:54 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Berthelsen Spencer R

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      7/2/25 4:52:41 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4)

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      5/2/25 4:38:26 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ionis Pharmaceuticals Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ionis Pharma upgraded by Barclays with a new price target

      Barclays upgraded Ionis Pharma from Equal Weight to Overweight and set a new price target of $57.00

      7/1/25 8:12:05 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Ionis Pharma with a new price target

      H.C. Wainwright initiated coverage of Ionis Pharma with a rating of Buy and set a new price target of $45.00

      4/7/25 8:43:57 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Redburn Atlantic initiated coverage on Ionis Pharma with a new price target

      Redburn Atlantic initiated coverage of Ionis Pharma with a rating of Neutral and set a new price target of $39.00

      3/31/25 8:13:04 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis Pharma downgraded by BMO Capital Markets with a new price target

      BMO Capital Markets downgraded Ionis Pharma from Outperform to Market Perform and set a new price target of $60.00 from $67.00 previously

      8/2/24 7:32:04 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis Pharma upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Ionis Pharma from Market Perform to Outperform and set a new price target of $62.00 from $53.00 previously

      7/24/24 7:31:03 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on Ionis Pharma with a new price target

      Jefferies resumed coverage of Ionis Pharma with a rating of Buy and set a new price target of $75.00 from $29.00 previously

      7/16/24 8:24:41 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis Pharma upgraded by Bernstein with a new price target

      Bernstein upgraded Ionis Pharma from Underperform to Mkt Perform and set a new price target of $44.00

      6/14/24 7:07:13 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis Pharma upgraded by Wolfe Research with a new price target

      Wolfe Research upgraded Ionis Pharma from Peer Perform to Outperform and set a new price target of $58.00

      4/10/24 8:41:43 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis Pharma upgraded by BofA Securities with a new price target

      BofA Securities upgraded Ionis Pharma from Neutral to Buy and set a new price target of $62.00 from $52.00 previously

      1/2/24 8:02:26 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis Pharma upgraded by BofA Securities with a new price target

      BofA Securities upgraded Ionis Pharma from Underperform to Neutral and set a new price target of $52.00 from $33.00 previously

      10/23/23 7:21:47 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ionis Pharmaceuticals Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Alltrna Announces Updates to Its Board of Directors

      Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

      7/17/24 8:00:00 AM ET
      $APRE
      $CYTK
      $EVLO
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

      Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

      6/24/24 4:05:00 PM ET
      $CTNM
      $IONS
      $NVS
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
      Medicinal Chemicals and Botanical Products
    • Ionis announces the appointment of Michael Yang to Board of Directors

      CARLSBAD, Calif., Dec. 14, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Board of Directors. Mr. Yang's appointment expands the total number of Ionis Board members to 10. Mr. Yang has more than 20 years of broad senior level leadership experience in biotech, pharmaceutical and medical device companies, where he launched new platforms, expanded global revenues and diversified product lines. He most recently served as President, Chief Executive Officer and B

      12/14/23 4:05:00 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TRACON Pharmaceuticals Announces Appointment of Lisa Johnson-Pratt, M.D., to its Board of Directors

      SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Lisa Johnson-Pratt, M.D., Senior Vice President, New Product Planning at Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), to its Board of Directors. “We are very pleased to welcome Lisa to TRACON’s Board of Directors,” said Dr. Charles Theuer, President and Chief Executive Officer of TRACON. “She is a physi

      3/8/21 8:05:00 AM ET
      $TCON
      $IONS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ionis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development officer

      CARLSBAD, Calif., Jan. 7, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the appointment of Eugene Schneider, M.D., as executive vice president and chief clinical development officer. In this role, Dr. Schneider will oversee clinical development of novel antisense medicines across all of Ionis' therapeutic franchises. He will report to Richard S. Geary, Ph.D., Ionis' executive vice president and chief development officer, and serve on the company's executive team. Since joining Ionis in 2013, Dr. Schneider has played a key role in more than 20 clinical trials conducted in the U.S. and globally. He is an accomplished biopharmaceutical industry veteran with

      1/7/21 5:30:00 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ionis Pharmaceuticals Inc. Financials

    Live finance-specific insights

    See more
    • Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

      Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersenBased on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to registrational stage studies, building on extensive experience in SMA CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced topline results from the Phase 1 study of

      6/25/25 7:30:37 AM ET
      $BIIB
      $IONS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ionis reports first quarter 2025 financial results

      - Encouraging start to first independent launch with TRYNGOLZATM - - On track for second independent launch with donidalorsen PDUFA August 21, 2025 - - Increasing 2025 financial guidance by more than 20% - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results for the first quarter ended March 31, 2025. "With an encouraging start to the TRYNGOLZA launch for familial chylomicronemia syndrome, the first of four independent launches expected over the next two years, Ionis' new chapter as a fully integrated, commercial-stage biotechnology company is well underway," said Brett P. Monia, Ph.D., chief executive officer, Ionis. "We look forward to continued m

      4/30/25 7:00:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results

      Up to four programs in registrational phase by 2025 Planned interim analysis for ulixacaltamide Essential3 Study 1 to be conducted in Q4 2024 Topline results for Phase 2 EMBOLD study of relutrigine (PRAX-562) in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) expected in Q3 2024 PRAX-628 Phase 2/3 POWER1 study to initiate in Q4 2024 Initiation of additional Phase 2 study (RADIANT) for PRAX-628 in focal and generalized epilepsy in 2H 2024, with topline results expected in 1H 2025 Cash and investments of $434 million as of June 30, 2024, maintains runway into 2027 BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a

      8/13/24 7:00:00 AM ET
      $IONS
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis reports second quarter 2024 financial results

      WAINUATM U.S. launch progressing well; approved in Canada; EU approval decision expected this year Olezarsen PDUFA December 19, 2024 for FCS Positive Phase 3 donidalorsen data for HAE; preparing U.S. and EU regulatory submissions On track to achieve 2024 financial guidance CARLSBAD, Calif., Aug. 1, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company"), today reported financial results for the second quarter of 2024. "Over the first half of this year, we continued to deliver on our goal to bring a steady cadence of medicines to people with serious dise

      8/1/24 7:00:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis reports first quarter 2024 financial results

      WAINUATM launch on track; EU and Canada approval decisions expected this year Olezarsen NDA submitted to FDA for FCS; preparing EU regulatory submission Positive Phase 3 donidalorsen data for HAE; preparing regulatory submissions On track to achieve 2024 financial guidance CARLSBAD, Calif., May 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company"), today reported financial results for the first quarter ended March 31, 2024. "Ionis is off to a great start in 2024, as we continue to execute on our vision to bring better futures to people with serious

      5/7/24 7:00:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis reports fourth quarter and full year 2023 financial results

      WAINUA™ approved with launch underway; on track for EU and Canada approval decisions this year Positive Phase 3 olezarsen and donidalorsen data, preparing regulatory submissions for FCS and HAE, respectively Olezarsen granted Breakthough Therapy designation by the FDA for FCS Ionis provides full year 2024 financial guidance CARLSBAD, Calif., Feb. 21, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company"), today reported financial results for the fourth quarter and full year ended December 31, 2023. "This past year included many remarkable achievements a

      2/21/24 7:00:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis reports second quarter 2023 financial results

      Reported Phase 3 data showing eplontersen continued to show improvement in ATTRv-PN through 85 weeks; December 22, 2023 PDUFA date Completed enrollment in donidalorsen OASIS-HAE study and eplontersen CARDIO-TTRansform ATTR-CM study keeping Phase 3 data readouts on track On track to achieve 2023 financial guidance CARLSBAD, Calif., Aug. 9, 2023 /PRNewswire/ -- – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company"), today reported financial results for the second quarter of 2023. Financial results are summarized below:   Three months ended June 30, Six months ended June 30,

      8/9/23 7:00:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis reports first quarter 2023 financial results

      QALSODY approved for SOD1-ALS; MAA under review in EU Reported positive Phase 3 eplontersen ATTRv-PN data; December 22, 2023 PDUFA date On track to achieve 2023 financial guidance CARLSBAD, Calif., May 3, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company"), today reported financial results for the first quarter of 2023. Financial results are summarized below: Three months ended March 31, 2023 2022 (amounts in millions) Total revenue $131 $142 Operating expenses $245 $199 Operating expenses on a non-GAAP basis $218 $173 Loss from operations ($114) ($5

      5/3/23 7:00:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis reports fourth quarter and full year 2022 financial results

      Eplontersen NDA submitted to FDA; tofersen under regulatory review for marketing approval in U.S. and EU Phase 3 data planned for eplontersen and olezarsen; robust late-stage pipeline expanding with two new Phase 3 programs Ionis provides full year 2023 financial guidance CARLSBAD, Calif., Feb. 22, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company"), a genetic medicines company, today reported financial results for the fourth quarter and full year ended December 31, 2022. Financial results are summarized below: Three months ended December 31, Year e

      2/22/23 7:01:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis' Genetic Medicines and Commercial Readiness

      Royalty Pharma to acquire an interest in SPINRAZA® and pelacarsen royalties – Ionis retains majority of royalties and all milestones from Novartis for pelacarsenRoyalty Pharma to pay Ionis $500 million upfront and up to $625 million in milestonesAgreement enables Ionis to achieve commercial readiness for multiple late-stage programs and advance its innovative pipeline of genetic medicines NEW YORK and CARLSBAD, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that Royalty Pharma has acquired an interest in Ionis' royalty in Biogen's SPINRAZA® (nusinersen) and Novartis' pelacarsen for up to $1.125 b

      1/9/23 9:15:00 AM ET
      $IONS
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ionis Pharmaceuticals Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4)

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      5/2/25 4:38:26 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hayden Michael R bought $181,079 worth of shares (5,000 units at $36.22), increasing direct ownership by 17% to 35,219 units (SEC Form 4)

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      12/26/24 4:57:52 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ionis Pharmaceuticals Inc. SEC Filings

    See more
    • Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

      6/12/25 9:00:44 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

      6/10/25 6:02:16 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

      5/19/25 7:18:21 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Ionis Pharmaceuticals Inc.

      10-Q - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

      4/30/25 3:56:17 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

      4/30/25 11:15:21 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Ionis Pharmaceuticals Inc.

      DEFA14A - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

      4/25/25 4:26:13 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Ionis Pharmaceuticals Inc.

      DEF 14A - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

      4/25/25 4:25:28 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

      3/11/25 8:38:50 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Ionis Pharmaceuticals Inc.

      10-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

      2/19/25 4:06:39 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

      2/19/25 11:15:25 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ionis Pharmaceuticals Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

      SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

      11/14/24 8:34:57 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

      SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

      11/14/24 1:28:29 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ionis Pharmaceuticals Inc.

      SC 13G - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

      11/8/24 10:52:38 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ionis Pharmaceuticals Inc.

      SC 13G - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

      2/14/24 10:04:34 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc. (Amendment)

      SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

      2/13/24 5:07:58 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc. (Amendment)

      SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

      2/13/24 6:09:26 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc. (Amendment)

      SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

      2/9/24 9:16:05 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc. (Amendment)

      SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

      6/9/23 2:15:39 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc. (Amendment)

      SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

      2/14/23 4:07:12 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ionis Pharmaceuticals Inc.

      SC 13G - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

      2/14/23 12:40:51 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ionis Pharmaceuticals Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA

      New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SPINRAZA® (nusinersen) Final results from the landmark NURTURE study highlight the profound impact of early treatment with 12 mg SPINRAZA in clinically presymptomatic SMA with 92% of children achieving the ability to walk independently CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). These latest findings from

      6/27/25 10:00:23 AM ET
      $BIIB
      $IONS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

      – Investigational salanersen (ION306/BIIB115) developed using novel Ionis antisense chemistry with the potential to achieve high efficacy and once-yearly dosing – – Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersen – – Biogen is engaging with regulators to advance salanersen to registrational stage studies – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that its partner, Biogen, shared positive topline results from the Phase 1 study of salanersen (ION306/BIIB115), an investigational antisense oligo

      6/25/25 7:31:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

      Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersenBased on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to registrational stage studies, building on extensive experience in SMA CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced topline results from the Phase 1 study of

      6/25/25 7:30:37 AM ET
      $BIIB
      $IONS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026

      Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that Richard Geary, Ph.D., executive vice president and chief development officer, will retire effective January 2026 and that Holly Kordasiewicz, Ph.D., currently senior vice president, neurology, will succeed him in the role. "Richard has made tremendous contributions to Ionis over his 30-year tenure during which he spearheaded dozens of development programs and brought six innovative medicines through regulatory approvals, including TRYNGOLZA, our first independent commercial medicine. We thank him for his leadership and unwavering dedication to patients in need," said Brett P. Monia, Ph.D., chief executive officer, Ionis. "Holl

      6/12/25 9:00:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

      - Completion of enrollment anticipated in 2026 - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the first participant has been dosed in the global Phase 3 REVEAL study, which is designed to evaluate the efficacy and safety of ION582, an investigational medicine for the treatment of people living with Angelman syndrome (AS), a serious and rare neurodevelopmental disorder that leads to significant physical and cognitive impairments. "Dosing the first person with Angelman syndrome in our pivotal REVEAL study marks an important milestone for this underserved community, who currently have no approved disease modifying treatments," said Holly Kordasiewicz, Ph.D., senior vice p

      6/11/25 7:00:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

      – Olezarsen met the primary endpoint with a statistically significant mean reduction in triglycerides versus placebo at 80 mg and 50 mg doses – – Olezarsen met all key secondary endpoints – – Olezarsen demonstrated a favorable safety and tolerability profile – – Nearly 1,500-person Phase 3 study supports the exposure database for olezarsen – – Data from pivotal Phase 3 CORE and CORE2 studies of olezarsen in severe hypertriglyceridemia (sHTG) expected in Q3 2025 – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced positive topline results from the Essence study of olezarsen in people with moderate hypertriglyceridemia (fasting triglycerides ≥150 mg/dL to <500 mg/dL) with or at risk f

      5/19/25 7:00:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis to host 2025 virtual Annual Meeting of Stockholders

      Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that management will conduct its 2025 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 5, 2025. The agenda for the event is as follows: 5:00 p.m. – 5:15 p.m. ET (2:00 p.m. – 2:15 p.m. PT) – Virtual Annual Meeting of Stockholders All stockholders of record at the close of business on April 7, 2025, are invited to participate in the virtual Annual Meeting webcast, which will be broadcast live at www.virtualshareholdermeeting.com/IONS2025. Stockholders of record will receive an official proxy card from their brokerage firm. Each proxy card contains a 16-digit control number required

      5/6/25 7:05:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event

      BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, hosted a virtual investor event on its clinical programs in developmental and epileptic encephalopathies (DEEs) on Friday, May 2, 2025. "We were excited to highlight the significant opportunity in DEEs and progress Praxis is making in this field," said Marcio Souza, president and chief executive officer of Praxis. "Relutrigine continues to show tremendous promise to broadly address the DEE market

      5/5/25 8:00:00 AM ET
      $IONS
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis reports first quarter 2025 financial results

      - Encouraging start to first independent launch with TRYNGOLZATM - - On track for second independent launch with donidalorsen PDUFA August 21, 2025 - - Increasing 2025 financial guidance by more than 20% - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results for the first quarter ended March 31, 2025. "With an encouraging start to the TRYNGOLZA launch for familial chylomicronemia syndrome, the first of four independent launches expected over the next two years, Ionis' new chapter as a fully integrated, commercial-stage biotechnology company is well underway," said Brett P. Monia, Ph.D., chief executive officer, Ionis. "We look forward to continued m

      4/30/25 7:00:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies

      – Despite currently available treatment options, the majority of surveyed adults with HAE reported making tradeoffs in their daily lives due to the unexpected and unpredictable nature of HAE attacks – – Opportunity exists for more consistent use of tools to support transparent communications between patients and their doctors, as HCPs may underestimate the full burden of HAE – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced results from a new survey showing that 91% of surveyed adults living with hereditary angioedema (HAE) were interested in trying a new prophylactic therapy, with nearly two-thirds (65%) reporting they haven't yet found the best treatment option for them. The I

      4/29/25 7:00:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care